Analogs of pridopidine, their preparation and use
View Patent ↗This invention provides an isolated compound having the structure: or a salt thereof. The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and. mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product. This invention also provides a process for producing a pridopidine drug product. This invention also provides a process of distributing a pridopidine drug product.
1. An isolated compound having the structure:
or a salt thereof.
2. A composition comprising pridopidine or a salt thereof and a compound which has the structure:
or a salt thereof.
3. A composition comprising a compound having the structure:
or a salt thereof, wherein the composition is free of Pridopidine or a salt thereof.
4. A pharmaceutical composition comprising an amount of pridopidine and at least one of
wherein
a) Compound 2 is present in the pharmaceutical composition in an amount not more than 10 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method, or
b) Compound 6 is present in the pharmaceutical composition in an amount not more than 10 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method.
5. The pharmaceutical composition of claim 4 , wherein
a) Compound 2 is present in the pharmaceutical composition in an amount not more than 0.15 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method, or
b) Compound 6 is present in the pharmaceutical composition in an amount not more than 0.15 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method.
6. The pharmaceutical composition of claim 5 , wherein
a) Compound 2 is present in the pharmaceutical composition in an amount greater than 0.01 area-%, and not more than 0.15 area-%, relative to the concentration of pridopidine, based on a determination by an HPLC method, or
b) Compound 6 is present in the pharmaceutical composition in an amount greater than 0.01 area-%, and not more than 0.15 area-%, relative to the concentration of pridopidine, based on a determination by an HPLC method.
7. The pharmaceutical composition of claim 5 , wherein
a) Compound 2 is present in the pharmaceutical composition in an amount less than 0.05 area %, relative to the concentration of pridopidine, based on a determination by an HPLC method, or
b) Compound 6 is present in the pharmaceutical composition in an amount less than 0.04 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method.
8. The pharmaceutical composition of claim 5 , wherein
a) Compound 2 is present in the pharmaceutical composition in an amount less than 0.01 area-%, relative to the concentration of pridopidine, based on a determination by an HPLC method, or
b) Compound 6 is present in the pharmaceutical composition in an amount less than 0.01 area-% relative to the concentration of pridopidine, based on a determination by an HPLC method.
9. The pharmaceutical composition of claim 4 , comprising pridopidine hydrochloride salt.
10. The pharmaceutical composition of claim 4 , in the form of a capsule, a tablet, a pill, a powder, a granule, a liquid solution or a liquid suspension.
11. The pharmaceutical composition of claim 10 , in an oral dosage unit form.
12. The pharmaceutical composition of claim 11 , wherein the oral dosage unit form comprises between 22.5-315 mg pridopidine.
13. The pharmaceutical composition of claim 12 , wherein the oral dosage unit form comprises between 45-250 mg pridopidine.
14. The pharmaceutical composition of claim 13 , wherein the oral dosage unit form comprises between 45-135 mg pridopidine.
15. The pharmaceutical composition of claim 11 , wherein the oral dosage unit form comprises between 90-315 mg pridopidine.
16. The pharmaceutical composition of claim 11 , wherein the oral dosage unit form comprises about22.5 mg pridopidine, about 45 mg pridopidine, about 67.5 mg pridopidine, about 90 mg pridopidine, about 100 mg pridopidine, about 112.5 mg pridopidine, about 125 mg pridopidine, about 135 mg pridopidine, about 150 mg pridopidine, about 180 mg pridopidine, about 200 mg pridopidine, about 250 mg pridopidine, or about 315mg pridopidine.
17. The pharmaceutical composition of claim 11 , wherein the oral dosage unit form is prepared for once daily administration.
18. The pharmaceutical composition of claim 11 , wherein the oral dosage unit form is prepared for more than once daily administration.
19. A process for preparing
comprising the steps of:
a) reacting 3-bromothioanisole with ethyl 3-(4-oxopiperidin-1-yl)propanoate to form 1-(3-hydroxy-3,3-bis(3-(methylthio)phenyl)propyI)-4-(3-(methylthio)phenyl) piperidin-4-ol,
b) dehydrating the 1-(3-hydroxy-3,3-bis(3-(methylthio)phenyl)propyl)-4-(3-(methylthio)phenyl)piperidin-4-ol formed in step a) with a dehydrating agent to obtain 1-(3,3-bis(3-(methylthio)phenyl)allyl-4-(3-(methylthio)phenyl-1,2,3,6-tetrahydropyridine,
c) oxidizing the 1-(3,3-bis(3-(methylthio)phenyl)allyl)-4-(3-(methylthio)phenyl)-1,2,3,6-tetrahydropyridine formed in step b) with an oxidizing agent to form 1-(3,3-bis(3-(methylsulfonyl)phenyl)allyI)-4-(3-(methylsulfonyl)phenyl)-1,2,3,6-tetrahydropyridine, and
d) hydrogenating the 1-(3,3-bis(3-(methylsulfonyl)phenyl)allyl)-4-(3-(methylsulfonyl)phenyl)-1,2,3,6-tetrahydropyridine formed in step c) with a hydrogenating agent to form Compound 2.
20. The process of claim 19 , wherein the dehydrating agent is a strong acid, preferably sulfuric acid.
21. The process of claim 19 , wherein the oxidizing agent is a peroxide, preferably hydrogen peroxide.
22. The process of claim 9 , wherein the hydrogenating agent is hydrogen.
23. A process for preparing
comprising the step of reacting 4-(3-(methylsuifonyl)phenyl)piperidine with 1-chloro-2-methylpentane to obtain Compound 6.
24. The composition of claim 2 , wherein the pridopidine salt is a pridopidine hydrochloride salt.